Characteristics and Outcomes of Hepatocellular Carcinoma in Patients with Autoimmune Hepatitis. in Digestive diseases and sciences / Dig Dis Sci. 2025 May 3. doi: 10.1007/s10620-025-09064-1.

2025
AOU Novara

Tipo pubblicazione

Journal Article

Autori/Collaboratori (32)Vedi tutti...

Pasta A
Gastroenterology Unit, Department of Internal Medicine, University of Genoa, Viale Benedetto XV, No. 6, 16132, Genoa, Italy.
Pieri G
Gastroenterology Unit, Department of Internal Medicine, University of Genoa, Viale Benedetto XV, No. 6, 16132, Genoa, Italy.
Plaz Torres MC
Gastroenterology Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.

et alii...

Abstract

BACKGROUND: The incidence of HCC in patients with autoimmune hepatitis (AIH) is low and, due to the paucity of data in the literature, a thorough characterization of these patients is missing. AIM: To describe the main characteristics and outcome of patients with AIH and HCC. METHODS: Among patients with HCC included in the Italian Liver Cancer (ITA.LI.CA) database during the period 2009-2022, we selected those with AIH, and we described their liver disease characteristics, modality of HCC diagnosis, tumor stage, treatment, and outcome. RESULTS: Among 10,026 patients with HCC, we identified 23 patients (0.2%) with AIH (43.5% males, 69.6% aged?>?65 years, 91.0% with cirrhosis). Fifteen patients (65.2%) had co-factors of liver disease [8 patients (34.8%) metabolic dysfunction-associated steatotic liver disease, 4 patients (17.4%) alcohol abuse, 3 patients (13.0%) AIH/Primary Biliary Cholangitis overlap syndrome]. Tumors diagnosed under surveillance (60.9%) were more frequently uninodular (85.7% vs 66.6%, p?=?0.146) and Milan-in (85.7% vs 44.4%, p?=?0.066) than those diagnosed outside surveillance. Treatment with curative intent was more frequent among patients under surveillance (78.6% vs 33.3%, p?=?0.077). Median overall survival was 41.7 months and was remarkably longer in patients under surveillance than in those diagnosed outside surveillance (68.2 vs 27.4 months, p?=?0.032). CONCLUSION: AIH accounts for a minimal fraction of patients with HCC, and in most patients, risk co-factors for HCC are present. In patients with AIH, too, surveillance is associated with better tumor stage, higher access rate to potentially curative treatments, and improved survival.

Accesso banca dati bibliografica

PMID : 40317369

DOI : 10.1007/s10620-025-09064-1

Keywords

Autoimmune hepatitis; Oncological outcomes; Risk stratification; Surveillance;